Clinical Policy: Corticosteroid Intravitreal Implants (Iluvien, Ozurdex, Retisert, Yutiq)
Reference Number: CP.PHAR.385
Effective Date: 05.29.18
Last Review Date: 11.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Dexamethasone (Ozurdex®) and fluocinolone acetonide (Iluvien®, Retisert®, Yutiq™) intravitreal implants contain a corticosteroid.

FDA Approved Indication(s)
Iluvien is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Ozurdex is indicated for the treatment of:
- Macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Non-infectious uveitis affecting the posterior segment of the eye
- Diabetic macular edema (DME)

Retisert and Yutiq are indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that corticosteroid intravitreal implants are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Macular Edema following BRVO or CRVO (must meet all):
      1. Diagnosis of macular edema following BRVO or CRVO;
      2. Request is for Ozurdex;
      3. Prescribed by or in consultation with an ophthalmologist;
      4. Age ≥ 18 years;
      5. Failure of intravitreal anti-vascular endothelial growth factor (VEGF) agents, unless contraindicated or clinically significant adverse effects are experienced (see Appendix B);
6. Dose does not exceed 1 implant per eye.

Approval duration: 4 weeks (one implant per eye)

B. Non-Infectious Uveitis (must meet all):
1. Diagnosis of non-infectious uveitis affecting the posterior segment of the eye;
2. Request is for Ozurdex, Retisert, or Yutiq;
3. Prescribed by or in consultation with an ophthalmologist;
4. Member meets one of the following (a or b):
   a. For Ozurdex, Yutiq: Age ≥ 18 years;
   b. For Retisert: Age ≥ 12 years;
5. Failure of both of the following (a and b), unless both are contraindicated or clinically significant adverse effects are experienced (see Appendix B):
   a. Systemic corticosteroid;
   b. Non-biologic immunosuppressive therapy;
6. Dose does not exceed 1 implant per eye.

Approval duration: 4 weeks (one implant per eye)

C. Diabetic Macular Edema (must meet all):
1. Diagnosis of DME;
2. Request is for Ozurdex or Iluvien;
3. Prescribed by or in consultation with an ophthalmologist;
4. Age ≥ 18 years;
5. Failure of intravitreal anti-VEGF agents, unless contraindicated or clinically significant adverse effects are experienced (see Appendix B);
6. Dose does not exceed 1 implant per eye.

Approval duration: 4 weeks (one implant per eye)

D. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Member meets one of the following (a, b, c or d):
   a. At least 4 months have passed since last treatment with Ozurdex;
   b. At least 12 months have passed since last treatment with Iluvien;
   c. At least 30 months have passed since last treatment with Retisert;
   d. At least 36 months have passed since last treatment with Yutiq;
4. Dose does not exceed 1 implant per eye.

Approval duration: 4 weeks (one implant per eye)
B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy. 
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   BRVO: branch retinal vein occlusion
   CRVO: central retinal vein occlusion
   DME: diabetic macular edema
   FDA: Food and Drug Administration
   VEGF: vascular endothelial growth factor

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| anti-VEGF agents (e.g., bevacizumab, Lucentis®, Eylea®) | **Macular Edema**
Refer to prescribing information | Refer to prescribing information |
| systemic corticosteroids (e.g., prednisone)                                      | **Uveitis**
prednisone 5 – 60 mg/day PO in 1 – 4 divided doses     | Varies |
| azathioprine (Azasan®, Imuran®)                                               | **Uveitis**
1.5 – 2 mg/kg/day PO                   | 2.5 mg/kg/day          |
| chlorambucil (Leukeran®)                                                       | **Uveitis**
0.2 mg/kg PO QD, then taper to 0.1 mg/kg PO QD or less   | 0.2 mg/kg/day          |
| cyclophosphamide (Cytoxan®)                                                   | **Uveitis**
1 – 2 mg/kg/day PO                        | N/A                 |
| cyclosporine (Sandimmune®, Neoral®)                                            | **Uveitis**
2.5 – 5 mg/kg/day PO in divided doses             | 5 mg/kg/day          |
| methotrexate (Rheumatrex®)                                                    | **Uveitis**                   | 30 mg/week          |
### Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

### Appendix C: Contraindications / Boxed Warnings

- **Contraindication(s):**
  - Iluvien, Ozurdex, Retisert, Yutiq: patients with active or suspected viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in active bacterial, mycobacterial or fungal infections of the eye.
  - Iluvien, Ozurdex: patients with glaucoma with cup to disc ratios of greater than 0.8.
  - Ozurdex: patients with posterior lens capsules that is torn or ruptured because of the risk of migration into the anterior chamber.
  - Iluvien, Ozurdex, Yutiq: hypersensitivity

- **Boxed warning(s):** none reported

### Appendix D: General Information

- **Based on clinical trials with Retisert:**
  - Within 3 years post-implantation, approximately 77% of patients will require intraocular pressure (IOP) lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure.
  - Following implantation of Retisert, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
  - During the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.

- **In one study, intravitreal bevacizumab (1.25 mg) and the dexamethasone (DEX) (0.7 mg) implant were compared in a randomized, Phase II trial called the BEVORDEX study.**
  - Forty-two eyes received intravitreal bevacizumab every 4 weeks, and 46 eyes received an intravitreal DEX (0.7 mg) implant every 16 weeks, with a when necessary (PRN) regimen for 12 months. The primary outcome of the study was to gain ten or more letters in the best-corrected distance visual acuity (BCVA) at 12 months, which was achieved in 40% of the bevacizumab-treated eyes and 41% of the DEX implant-treated group (P=0.99). The mean corneal refractive therapy (CRT) decrease was statistically significant between the groups, and the reduction was 122 μm in the bevacizumab group and 187 μm in the DEX implant group (P=0.015). The mean number of injections over 1 year was 8.6 for the bevacizumab group and 2.7 for the DEX implant group. Finally, in the DEX implant-treated eyes, 11% lost ten or more letters of the BCVA, which was due to cataracts in 4 of 5 cases; none lost ten letters in the bevacizumab-treated eyes.
• The Chart Review of Ozurdex in Macular Edema (CHROME) study evaluated the real-world use, efficacy, and safety of one or more dexamethasone intravitreal implant(s) 0.7 mg (DEX implant) in 120 eyes with macular edema (ME). The mean number of DEX implant injections was 1.7±0.1 in all study eyes; 44.2% of eyes had repeat DEX implant injections (reinjection interval 2.3-4.9 months).

• According to Pommier et al., an average of 2.6 injections of Ozurdex were needed to obtain a 58.6% of patients who gained more than 15 letters, and 51.1% of patients showed macular edema resolution.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Macular edema, uveitis</td>
<td>Inject the implant containing 0.7 mg dexamethasone</td>
<td>One implant injection per eye</td>
</tr>
<tr>
<td>(Ozurdex)</td>
<td></td>
<td>intravitreally</td>
<td>every 4 months</td>
</tr>
<tr>
<td>Fluocinolone</td>
<td>Diabetic macular edema</td>
<td>Inject the implant containing 0.19 mg fluocinolone</td>
<td>One implant injection per eye</td>
</tr>
<tr>
<td>(Iluvien)</td>
<td></td>
<td>intravitreally</td>
<td>every 12 months</td>
</tr>
<tr>
<td>Fluocinolone</td>
<td>Uveitis</td>
<td>Inject the implant containing 0.59 mg fluocinolone</td>
<td>One implant injection per eye</td>
</tr>
<tr>
<td>(Retisert)</td>
<td></td>
<td>intravitreally</td>
<td>every 30 months</td>
</tr>
<tr>
<td>Fluocinolone</td>
<td></td>
<td>Inject the implant containing 0.18 mg fluocinolone</td>
<td>One implant injection per eye</td>
</tr>
<tr>
<td>(Yutiq)</td>
<td></td>
<td>intravitreally</td>
<td>every 36 months</td>
</tr>
</tbody>
</table>

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Biodegradable intravitreal implant: 0.7 mg</td>
</tr>
<tr>
<td>(Ozurdex)</td>
<td></td>
</tr>
<tr>
<td>Fluocinolone</td>
<td>Non-biodegradable intravitreal implant: 0.19 mg</td>
</tr>
<tr>
<td>(Iluvien)</td>
<td></td>
</tr>
<tr>
<td>Fluocinolone</td>
<td>Non-biodegradable intravitreal implant: 0.59 mg</td>
</tr>
<tr>
<td>(Retisert)</td>
<td></td>
</tr>
<tr>
<td>Fluocinolone</td>
<td>Non-biodegradable intravitreal implant: 0.18 mg</td>
</tr>
<tr>
<td>(Yutiq)</td>
<td></td>
</tr>
</tbody>
</table>

VII. References
CLINICAL POLICY
Corticosteroid Intravitreal Implants


Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7311</td>
<td>Injection, fluocinolone acetonide intravitreal implant, 0.59 mg (Retisert)</td>
</tr>
<tr>
<td>J7312</td>
<td>Injection, dexamethasone intravitreal implant, 0.1 mg</td>
</tr>
<tr>
<td>J7313</td>
<td>Injection, fluocinolone acetonide intravitreal implant, 0.19 mg (Iluvien,)</td>
</tr>
<tr>
<td>J7314</td>
<td>Injection, fluocinolone acetonide intravitreal implant, 0.18 mg (Yutiq)</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th></th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>05.29.18</td>
<td>08.18</td>
</tr>
<tr>
<td>3Q 2019 annual review: added description, initial and continuation criteria, administration, and HCPCS codes for Yutiq; consolidated contraindications; references reviewed and updated</td>
<td>05.20.19</td>
<td>08.19</td>
</tr>
<tr>
<td>Updated JCODE for Yutiq from J7313 to J7314 (effective 10/1/19)</td>
<td>08.22.19</td>
<td></td>
</tr>
<tr>
<td>3Q 2020 annual review: added HIM line of business, removed HIM-Medical Benefit; removed required step through of intravitreal steroid injections from all indications due to lack of commercial availability (Triescence is the only intravitreal steroid injection on market, and it is currently on shortage without a known resolution date); references reviewed and updated.</td>
<td>06.22.20</td>
<td>08.20</td>
</tr>
<tr>
<td>Revised dosing frequency for Ozurdex from q6 months to q4 months per literature review, guideline recommendations, market analysis, and specialist feedback.</td>
<td>08.19.20</td>
<td>11.20</td>
</tr>
</tbody>
</table>
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.
Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.